Novartis’ radiogland therapy (RLT) Pluvicto – lutetium Lu 177 vipivotide tetraxetan – has received its first approval in Europe as a treatment for advanced prostate cancer from the Medicines and ...

Eli Lilly has announced an additional investment of $4.5bn across two of its three sites in Indiana in the US, bringing the company’s total Indiana capital expansion commitments since 2020 to more ...

We’re delighted that Amiculum has become a member of Bionow, joining a collaborative community that plays an important role ...

Angelini Pharma has announced that it will acquire Catalyst Pharmaceuticals in a deal worth around $4.1bn (3.5bn euros).

Langland has appointed Victoria Kent as Managing Partner, Medical Strategy & Education, with responsibility for all medical ...

Sanofi’s Tzield (teplizumab) has received expanded approved from the US FDA, allowing it to be used for children aged one ...

GC Therapeutics has appointed Stefan Irion as Chief Scientific Officer (CSO). Irion brings more than two decades of experience translating stem cell science into clinical stage therapeutics. In his ...

The US FDA has granted Rare Paediatric Disease (RPD) designation for Satellite Bio’s SB-101 for the treatment of urea cycle disorders (UCDs)., Satellite Bio is a biotechnology company developing ...

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and ...

Did you know? Over 320,000 learners have engaged with heart failure content on Medscape. With such an enthusiastic audience ...

Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, ...

Biogen has entered into an agreement with TJ Biopharma (TJ Bio) to acquire exclusive rights to felzartamab in the Greater ...